AZD3355 Dose-escalation Study in Healthy Males

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The aim is to establish the maximal tolerated dose of AZD3355 for the selection of doses in the up-coming studies. This will be done by comparing single and repeated doses of AZD3355 to placebo ("inactive substance"). Safety and tolerability variables will be closely monitored throughout the study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Lesogaberan

Criteria

Inclusion Criteria:

• Subjects without concurrent diseases who do not require any medical treatments

• Provision of signed informed consent.

Exclusion Criteria:

• History of somatic disease/condition, which may interfere with the objectives for the study, as judged by the investigator.

• Clinically significant illness or clinically relevant trauma within the 2 weeks prior to the administration of the investigational product, as judged by the investigator.

• History of clinically significant orthostatic reaction or syncope

• Clinically important abnormalities related to the heart function